Pamidronate in the Prevention of Chemotherapy-Induced Bone Loss in Premenopausal Women with Breast Cancer: A Randomized Controlled Trial | Zendy

Ghada ElHajj Fuleihan | Zendy; Mariana Salamoun | Zendy; Yasser Abou Mourad | Zendy; Aref Chehal | Zendy; Ziad Salem | Zendy; Ziyad Mahfoud | Zendy; Ali Shamseddine | Zendy

Open Access

Pamidronate in the Prevention of Chemotherapy-Induced Bone Loss in Premenopausal Women with Breast Cancer: A Randomized Controlled Trial

Author(s) -

Ghada ElHajj Fuleihan,

Mariana Salamoun,

Yasser Abou Mourad,

Aref Chehal,

Ziad Salem,

Ziyad Mahfoud,

Ali Shamseddine

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-1444

Subject(s) - medicine , breast cancer , amenorrhea , chemotherapy , bone mineral , placebo , bone remodeling , randomized controlled trial , osteoporosis , hypoestrogenism , surgery , urology , cancer , pregnancy , alternative medicine , pathology , biology , genetics

Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy. Sequelae of therapy include ovarian failure and bone loss, loss that would increase these patients' risk of fracture with aging. In this study, we assessed the efficacy of pamidronate in preventing such loss.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research